• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antiplatelet agents for chronic kidney disease
CONCLUSIONS: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.PMID:35224730 | DOI:10.1002/14651858.CD008834.pub4
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Valeria M Saglimbene Marinella Ruospo Mona Razavian Jonathan C Craig Meg J Jardine Angela C Webster Giovanni Fm Strippoli Source Type: research

Risk of hospital admission or emergency department presentation due to diabetes complications: a retrospective cohort study in Tasmania, Australia
ConclusionsOur results demonstrated the high demand on hospital services due to diabetes complications (especially macrovascular complications) and highlighted the importance of preventing and properly managing microvascular complications. These findings will support future resource allocation to reduce the increasing burden of diabetes in Australia.PMID:37137728 | DOI:10.1071/AH22271
Source: Australian Health Review - May 3, 2023 Category: Hospital Management Authors: Ngan T T Dinh Barbara de Graaff Julie A Campbell Matthew D Jose John Burgess Timothy Saunder Alex Kitsos Petr Otahal Andrew J Palmer Source Type: research

Cardiovascular Risk Factors and Events in Pancreas-Kidney Transplants
Abstract: Cardiovascular and cerebrovascular disease (CCVD) are major causes of morbidity and mortality among patients with diabetes. Strict control of treatable risk factors that contribute to atherosclerosis is important to reduce the risk of stroke, myocardial infarction, and peripheral arterial disease. Simultaneous pancreas-kidney transplantation (SPKT) may significantly improve these risk factors in patients with type 1 diabetes. We studied 103 SPKT from our center with both organs functioning for metabolic and hypertensive control; body mass index (BMI); immunosuppression; and CCVD events. The 53 females/50 males s...
Source: Transplantation Proceedings - April 1, 2013 Category: Transplant Surgery Authors: L. Martins, I. Fonseca, L. Dias, J. Malheiro, A. Rocha, P. Azevedo, H. Silva, R. Almeida, A.C. Henriques, J. Davide, A. Cabrita Tags: Renal Transplantation Source Type: research

Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial
Conclusions BP-lowering treatment with an ARB did not significantly lower the risks of major cardiovascular events or death among patients with hypertension on chronic HD. (Cochrane Renal Group Prospective Trial Register number CRG010600030).
Source: Nephrology Dialysis Transplantation - June 18, 2013 Category: Urology & Nephrology Authors: Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, Arima, Chinen, Tokashiki, Hirano-Nakasone, N Tags: Intra- and Extracorporeal Treatment of Kidney Failure Source Type: research

Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study
Conclusions: In a cohort of participants with CKD, low serum bicarbonate level was an independent risk factor for kidney disease progression, particularly for participants with preserved kidney function. The risk of heart failure was higher at the upper extreme of serum bicarbonate levels. There was no association between serum bicarbonate level and all-cause mortality or atherosclerotic events.
Source: American Journal of Kidney Diseases - March 13, 2013 Category: Urology & Nephrology Authors: Mirela Dobre, Wei Yang, Jing Chen, Paul Drawz, L. Lee Hamm, Edward Horwitz, Thomas Hostetter, Bernard Jaar, Claudia M. Lora, Lisa Nessel, Akinlolu Ojo, Julia Scialla, Susan Steigerwalt, Valerie Teal, Myles Wolf, Mahboob Rahman, CRIC Investigators Tags: Pathogenesis and Treatment of Kidney Disease Source Type: research

Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease
Conclusions Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements of FGF23 have no added value over a single value to predict the cardiovascular outcome. This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 years' time is small. Concomitantly, this study showed no benefit of consecutive FGF23 testing for estimating the risk of a clinical event in an individual patient.
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Bouma-de Krijger, A., Bots, M. L., Vervloet, M. G., Blankestijn, P. J., ter Wee, P. W., van Zuilen, A. D., Wetzels, J. F. Tags: Chronic Kidney Disease Source Type: research

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Conclusions Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114)
Source: Nephrology Dialysis Transplantation - February 28, 2014 Category: Urology & Nephrology Authors: Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., Tegegne, G. G. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients
Conclusions In incident HD patients, ferumoxytol showed similar short- to mid-term safety profiles with regard to cardiovascular, infectious and mortality outcomes compared with the more commonly used intravenous iron formulations IS and FG.
Source: Nephrology Dialysis Transplantation - November 23, 2015 Category: Urology & Nephrology Authors: Airy, M., Mandayam, S., Mitani, A. A., Chang, T. I., Ding, V. Y., Brookhart, M. A., Goldstein, B. A., Winkelmayer, W. C. Tags: Intra- and extracorporeal treatments of kidney failure Source Type: research

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
CONCLUSIONS: We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD. PMID: 26671531 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 16, 2015 Category: Journals (General) Authors: Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G Tags: Cochrane Database Syst Rev Source Type: research

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Background Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin–angiotensin aldosterone system are the mainstay of therapy for chronic kidney disease (CKD). Research has confirmed the benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in advanced CKD are lacking. In the STOP-ACEi trial, we aim to confirm preliminary findings which suggest that withdrawal of ACEi/ARB treatment can stabilize or even improve renal function in patients with advanced progressive CKD. Methods The STOP-ACEi trial (tri...
Source: Nephrology Dialysis Transplantation - January 25, 2016 Category: Urology & Nephrology Authors: Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., El Nahas, M. Tags: Chronic Kidney Disease Source Type: research

Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)
Conclusion In Asian type 2 diabetic patients with chronic kidney disease and heavy proteinuria, reduction of SBP ≤ 130 mmHg was associated with greater renoprotection than cardioprotection. However, our results emphasize the need to individualize BP targets in type 2 diabetes.
Source: Nephrology Dialysis Transplantation - February 22, 2016 Category: Urology & Nephrology Authors: Imai, E., Ito, S., Haneda, M., Harada, A., Kobayashi, F., Yamasaki, T., Makino, H., Chan, J. C. N. Tags: Chronic Kidney Disease Source Type: research

Pages: 1  2  3  4